Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin αVβ3 |
| |
Authors: | Dr André Raposo?Moreira?Dias Dr Lizeth Bodero Ana Martins Dr Daniela Arosio Dr Silvia Gazzola Prof?Dr Laura Belvisi Dr Luca Pignataro Dr Christian Steinkühler Dr Alberto Dal?Corso Prof?Dr Cesare Gennari Prof?Dr Umberto Piarulli |
| |
Affiliation: | 1. Università degli Studi di Milano, Dipartimento di Chimica, Via C. Golgi, 19, 20133 Milan, Italy;2. Università degli Studi dell'Insubria, Dipartimento di Scienza e Alta Tecnologia, Via Valleggio, 11, 22100 Como, Italy;3. Exiris Srl, Via di Castel Romano, 100, 00128 Rome, Italy;4. CNR, Istituto di Scienze e Tecnologie Molecolari (ISTM), Via C. Golgi, 19, 20133 Milan, Italy |
| |
Abstract: | This work reports the synthesis of a series of small-molecule–drug conjugates containing the αVβ3-integrin ligand cycloDKP-RGD] or cycloDKP-isoDGR], a lysosomally cleavable Val-Ala (VA) linker or an “uncleavable” version devoid of this sequence, and monomethyl auristatin E (MMAE) or F (MMAF) as the cytotoxic agent. The conjugates were obtained via a straightforward synthetic scheme taking advantage of a copper-catalyzed azide–alkyne cycloaddition as the key step. The conjugates were tested for their binding affinity for the isolated αvβ3 receptor and were shown to retain nanomolar IC50 values, in the same range as those of the free ligands. The cytotoxic activity of the conjugates was evaluated in cell viability assays with αvβ3 integrin overexpressing human glioblastoma (U87) and human melanoma (M21) cells. The conjugates possess markedly lower cytotoxic activity than the free drugs, which is consistent with inefficient integrin-mediated internalization. In almost all cases the conjugates featuring isoDGR as integrin ligand exhibited higher potency than their RGD counterparts. In particular, the cycloDKP-isoDGR]-VA-MMAE conjugate has low nanomolar IC50 values in cell viability assays with both cancer cell lines tested (U87: 11.50±0.13 nm ; M21: 6.94±0.09 nm ) and is therefore a promising candidate for in vivo experiments. |
| |
Keywords: | antitumor agents auristatins drug delivery integrins peptidomimetics |
|
|